British oncology company in Edinburgh, founded in 2018, which builds new cancer drug ventures from academic and industrial discoveries. Runs a portfolio model in which it identifies promising oncology assets and targets, sets up separate companies around them and takes them through preclinical and early clinical development using a network of contract researchers and advisers, and works with academic groups in Scotland and beyond.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen